Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
31 Julho 2023 - 5:29PM
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or
“Tarsus”), whose mission is to focus on unmet needs and apply
proven science and new technology to revolutionize treatment for
patients, starting with eye care, today announced the commencement
of an underwritten public offering of $100.0 million of shares of
its common stock. Tarsus also intends to grant the underwriters a
30-day option to purchase up to an additional $15.0 million of
shares of common stock offered in the proposed offering. All shares
in the proposed offering are to be sold by Tarsus. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, BofA Securities, Guggenheim
Securities, LLC and Oppenheimer & Co. are acting as joint
book-running managers for the offering.
A registration statement relating to the shares to be sold in
the proposed offering has been filed with the U.S. Securities and
Exchange Commission (SEC) as was declared effective on November 5,
2021. Copies of the registration statement can be accessed through
the SEC’s website at www.sec.gov. The offering will be made only by
means of prospectus. A preliminary prospectus supplement related to
the offering (including the accompanying prospectus) will be filed
with the SEC and will be available on the SEC’s website located
at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus may also be obtained,
when available, from: Goldman Sachs & Co. LLC, Attention:
Prospectus Department, 200 West Street, New York, New York 10282,
by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; BofA Securities, NC1-022-02-25, 201
North Tryon Street, Charlotte, North Carolina 28255-0001,
Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; Guggenheim Securities, LLC,
Attention: Equity Syndicate Department, 330 Madison Avenue, 8th
Floor, New York, NY 10017, by telephone at (212) 518-9544, or by
email at GSEquityProspectusDelivery@guggenheimpartners.com; or
Oppenheimer & Co. Inc., Attention: Syndicate Prospectus
Department, 85 Broad Street, 26th Floor, New York, New York 10004,
by telephone at (212) 667-8055, or by email at
EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Tarsus Pharmaceuticals, Inc.Tarsus
Pharmaceuticals, Inc. applies proven science and new technology to
revolutionize treatment for patients, starting with eye care.
Tarsus is advancing its pipeline to address several diseases with
high unmet need across a range of therapeutic categories, including
eye care, dermatology, and infectious disease prevention. XDEMVY™
(lotilaner ophthalmic solution) 0.25% is FDA approved in the United
States for the treatment of Demodex blepharitis. Tarsus is also
developing TP-03 for the treatment of Meibomian Gland Disease,
which is currently being studied in a Phase 2a clinical trial. In
addition, Tarsus is developing TP-04 for the potential treatment of
Rosacea and TP-05, an oral tablet for the prevention of Lyme
disease. TP-04 and TP-05 are both currently being studied in Phase
2a clinical trials to evaluate safety, tolerability, and proof-of
activity.
Forward-Looking StatementsStatements in this
press release about future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements.” The
words, without limitation, “believe,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these or
similar identifying words. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors; including, but not limited to, risks
and uncertainties related to market conditions, and satisfaction of
customary closing conditions related to the proposed public
offering and the grant to the underwriters of an option to purchase
additional shares. Further, there are other risks and
uncertainties that could cause actual results to differ from those
set forth in the forward-looking statement and they are detailed
from time to time in the reports Tarsus files with the Securities
and Exchange Commission, including Tarsus’ Form 10-K for the year
ended December 31, 2022 filed on March 17, 2023 with the SEC, which
Tarsus incorporates by reference into this press release, copies of
which are posted on its website and are available from Tarsus
without charge. However, new risk factors and uncertainties may
emerge from time to time, and it is not possible to predict all
risk factors and uncertainties. Accordingly, readers are cautioned
not to place undue reliance on these forward-looking statements.
Any forward-looking statements contained in this press release are
based on the current expectations of Tarsus’ management team and
speak only as of the date hereof, and Tarsus specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Contacts: Media Contact:Adrienne KempSr.
Director, Corporate Communications(949)
922-0801akemp@tarsusrx.com
Investor Contact:David NakasoneHead of Investor Relations(949)
620-3223DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024